Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success
Drug Targets apoC-III To Lower Triglycerides
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.
